NASDAQ$BTAI
Bioxcel Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
BioXcel Therapeutics Inc reported Q1 2026 results showing product revenue of $206,000 amid strategic commercialization adjustments and continued R&D focus.
The company generated $206,000 in product revenue for the quarter ended March 31, 2026, primarily from IGALMI sales under a revised hospital-focused strategy. Net loss widened to $12.69 million due to operating expenses of $10.43 million, while cash and cash equivalents stood at $17.18 million, supporting operations into the second quarter of 2026. Key developments included sNDA submission for at-home use of IGALMI and ongoing clinical prioritization.
- Product revenue totaled $206,000 in Q1 2026, reflecting limited commercialization resources post-Clinical Reprioritization.
- Research and development expenses decreased to $2.96 million from $4.55 million in the prior-year quarter.
- Net loss reached $12.69 million with cash position at $17.18 million providing runway into Q2 2026.
- sNDA filed for IGALMI at-home indication with PDUFA target date of November 14, 2026.
Headline financials
Revenue & EPS history
Bioxcel Therapeutics · Revenue · Quarterly
$206K
Revenue by segment
Bioxcel Therapeutics · $206K total across 1 segment · Q1 2026
- IGALMI$206K—100.0%
Forward guidance
Company advancing sNDA for IGALMI at-home use with PDUFA date of November 14, 2026 while prioritizing clinical programs and managing liquidity.
Tailwinds
- sNDA accepted for at-home IGALMI indication
- SERENITY At-Home trial met primary safety endpoint
Headwinds
- Substantial doubt about going concern
- Limited cash runway into Q2 2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-3.1%
Avg return
Earnings day
-5.6%
Avg return
5 days after
-10.0%
Avg return
30 days after
30%
10 / 33 earnings
Positive
+38.7%
Q3 2022
Best reaction
-44.1%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.8% | -9.9% | — | |
| Q4 2025 | -5.6% | -10.9% | -22.6% | |
| Q3 2025 | -16.0% | -9.4% | -0.5% | |
| Q2 2025 | +6.5% | -14.4% | -47.0% | |
| Q1 2025 | +0.0% | -4.8% | +6.8% | |
| Q4 2024 | +6.0% | -11.9% | -14.2% | |
| Q3 2024 | -8.2% | -2.6% | -33.4% | |
| Q2 2024 | -1.0% | -20.5% | -35.9% | |
| Q1 2024 | -1.4% | +0.5% | -33.3% | |
| Q4 2023 | -1.0% | -7.6% | -3.8% | |
| Q3 2023 | -20.1% | -25.0% | -41.2% | |
| Q2 2023 | -44.1% | -41.5% | -54.3% | |
| Q1 2023 | +17.7% | +18.6% | -9.6% | |
| Q4 2022 | -27.2% | -28.3% | -39.1% | |
| Q3 2022 | +38.7% | +41.1% | +49.2% | |
| Q2 2022 | -9.7% | -5.9% | -9.4% | |
| Q1 2022 | -10.6% | -6.5% | -6.7% | |
| Q4 2021 | -8.3% | -20.3% | -9.4% | |
| Q3 2021 | -2.4% | -19.7% | -35.5% | |
| Q2 2021 | +2.2% | -1.6% | +19.3% | |
| Q1 2021 | +8.1% | +3.1% | +27.2% | |
| Q4 2020 | +3.8% | +2.0% | -20.7% | |
| Q3 2020 | -4.1% | -8.6% | -23.8% | |
| Q2 2020 | -4.7% | -6.3% | +0.5% | |
| Q1 2020 | +0.1% | +9.6% | +6.7% | |
| Q4 2019 | -3.9% | -39.8% | -35.5% | |
| Q3 2019 | +12.4% | +40.6% | +48.3% | |
| Q2 2019 | -15.1% | -7.5% | +2.6% | |
| Q1 2019 | +12.8% | +9.4% | +5.3% | |
| Q4 2018 | -6.6% | +12.3% | +23.1% | |
| Q3 2018 | -7.9% | -12.6% | -21.8% | |
| Q2 2018 | -1.8% | -9.6% | -8.5% | |
| Q1 2018 | -4.9% | +3.6% | -1.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro